Cardiogen
Cardiac Bioregulatory Tetrapeptide | Cardiovascular & Tissue Repair
On this page
What is Cardiogen?
Cardiogen is a lab-made four-amino-acid peptide (called a bioregulator) developed by Russian researchers to study cardiac tissue in cell cultures and animal models. Published research looks at how it interacts with heart-muscle cells in laboratory settings, with no human clinical trials conducted to date. It's sold here strictly as a research chemical for laboratory study, not for use in people or animals.
Key terms:
Cardiogen is a synthetic tetrapeptide.
Cardiogen (Ala-Glu-Asp-Arg, or AEDR) is a lab-made peptide of four amino acids. It belongs to the bioregulator family developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Lab work reports that it acts on heart tissue in three ways: it changes how fibroblasts (connective-tissue cells) multiply, it lowers p53 activity so fewer heart-muscle cells self-destruct, and it increases proteins of the cell skeleton and the nuclear matrix. Preclinical studies have looked at cardiac remodeling, recovery from heart-muscle injury, and age-related heart decline. Every published study so far is a cell-culture (in vitro) experiment or an animal model.
Key research areas
- Direct systemic delivery for cardiac tissue support
- Established reconstitution protocols
- Most commonly studied administration route in preclinical research
Researched dosing
This table reflects dosing schedules used in community and preclinical research settings for Cardiogen — presented as research-methodology reference, not usage instructions.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Standard protocol (community-derived) | 10mg | Every 3-7 days | SubQ |
| Higher-dose protocol (community-derived) | 20mg | Every 3-7 days | SubQ |
| Extended course (community-derived) | 10-20mg | Weekly for up to 16 weeks | SubQ |
Commonly cycled 4 weeks on, 12+ weeks off.
How it works
At the cell level, Cardiogen research looks at how the peptide interacts with heart-muscle cells (cardiomyocytes) and supporting tissue cells (fibroblasts) in cultured and animal studies — the terms below are just the biology names for those cell types and processes.
Subcutaneous injection provides systemic distribution allowing AEDR tetrapeptide to reach cardiac tissue and modulate fibroblast proliferation and cardiomyocyte apoptosis pathways
Molecular data
These figures — molecular weight, chain length, sequence — are the chemistry ID researchers use to confirm a Cardiogen sample is the four-amino-acid AEDR sequence it's meant to be.
- Weight
- 489.47 Da
- Length
- 4 amino acids
- Type
- Tetrapeptide
Ala-Glu-Asp-Arg (AEDR)
Research applications
This section summarizes the research areas — cardiac tissue, cellular health, and longevity pathways — that preclinical studies have looked at for Cardiogen, based entirely on cell-culture and animal-model data, not human trials.
Cardiovascular
Preclinical models suggest cardiomyocyte proliferation stimulation and apoptosis suppression through p53 downregulation. Coronary artery ligation mouse models suggest reduced necrotic zones and improved survival outcomes. Stimulates cardiac cell proliferation in both young and aged tissue cultures, potentially addressing age-related cardiovascular deterioration.
Cellular
Cellular-level effects on cardiac tissue through modulation of fibroblast proliferation and cardiomyocyte apoptosis pathways.
Longevity
Potential longevity effects through cardiac tissue support and cellular regeneration based on preclinical data.
Dosage reference
- Doses used in research
- 10–20 mg per dose
- Frequency in studies
- Every 3-7 days
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Research protocols typically run 2-4 weeks; effects studied in preclinical models only
- Storage
- Refrigerate at 2-8°C, use within 30 days after reconstitution
- Cycle length
- 2-4 weeks
- Break between cycles
- 3-6 months between cycles
Interactions
This list shows which other peptides researchers and the community study alongside Cardiogen, and why.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried Cardiogen powder into a liquid research solution using bacteriostatic water.
- Allow vial to reach room temperature (15-20 minutes)
- Clean vial top with alcohol swab and allow to dry
- Calculate required bacteriostatic water volume using the calculator below
- Draw calculated volume of bacteriostatic water into syringe
- Inject water slowly down the inside wall of the vial (never directly onto powder)
- Gently swirl until powder completely dissolves (never shake)
- Solution should be clear - discard if cloudy or contains particles
Lyophilized: Room temperature, use within Stable until expiration date
Reconstituted: 2-8°C, use within 30 days
Open the Cardiogen reconstitution calculatorQuality indicators
These are the checks — powder appearance, solution clarity, lab-report verification — researchers use to confirm a Cardiogen sample is pure and correctly identified before use in a study.
White Lyophilized Powder - Pure Cardiogen appears as white to off-white lyophilized powder or cake
Clear Reconstituted Solution - Properly reconstituted solution should be crystal clear with no particles or cloudiness
Certificate of Analysis - Should include HPLC purity verification (>97%), sequence confirmation (AEDR), and mass spectrometry data
Research Use Only - Cardiogen is not approved for human use - ensure proper research context and documentation
Discolored or Cloudy Solution - Yellow, brown, or cloudy reconstituted solution indicates degradation - do not use
What to expect
This timeline summarizes what animal and cell-culture research reports at each study stage — theoretical research context, not a personal-results promise.
No significant observable changes expected
Preclinical research suggests cellular-level effects on cardiac tissue
Benefits are theoretical based on animal and in vitro data only
Safety notes
This section covers handling cautions and regulatory notes for Cardiogen — it is not approved for human use by any regulatory agency, and this is research-use-only scope, not medical advice.
- Not recommended during active cancer due to proliferative effects on fibroblasts
- Contraindicated in pregnancy and lactation due to absence of safety data
- Medical supervision recommended
- Not approved for human use by any regulatory agency
- All published research is preclinical (animal and in vitro studies)
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
Tetrapeptide H-Ala-Glu-Asp-Arg-OH enhanced expression of cytoskeletal proteins (actin, tubulin, vimentin) by 2-5 times and nuclear matrix proteins (lamin A, lamin C) by 2-3 times in cultured mouse embryonic fibroblasts, establishing the mechanism for its cardioprotective activity.
Cardiogen demonstrated significant stimulating effect on cell proliferation in myocardial tissue from both young and old rats. Immunohistochemical analysis showed decreased p53 protein expression, indicating inhibition of apoptosis in cardiac tissue.
Dose-dependent inhibition of M-1 sarcoma growth through hemorrhagic necrosis and stimulation of tumor cell apoptosis. Mechanism operated through disruption of tumor vascular network rather than direct cytostatic effects.